key: cord-0866070-hpxgab2b authors: Luethy, Paul M; Johnson, J Kristie title: Comparison of three sample-to-answer RT-PCR testing platforms for the detection of SARS-CoV-2 RNA in positive nasopharyngeal and nasal swabs date: 2021-06-22 journal: J Appl Lab Med DOI: 10.1093/jalm/jfab066 sha: 80005b43e7ff02c92598ff1a5883113022988d89 doc_id: 866070 cord_uid: hpxgab2b INTRODUCTION: The COVID-19 pandemic has strained clinical microbiology laboratories due to testing supply allocations. As a result, laboratories have had to invest in multiple COVID-19 assays performed on different testing instruments. Comparing the results achieved by testing positive samples between in-use assays can provide insights into which platforms may be interchangeable for testing in times of supply chain emergencies. METHODS: Nasopharyngeal and nasal swab specimens collected in viral transport media that tested positive on the Xpert® Xpress SARS-CoV-2 assay were tested on the ePlex® SARS-CoV-2 and BD SARS-CoV-2 Reagents for BD Max™ assays. Positive percent agreement was calculated using the Xpert® Xpress SARS-CoV-2 assay as the reference method. RESULTS: We tested 78 positive swabs, resulting in a positive percent agreement (PPA) of 92% [CI 84-97%] for the BD SARS-CoV-2 assay and 58% [CI 47-70%] for the ePlex® assay. Following development of a new workflow for the ePlex®, we detected SARS-CoV-2 in 7 additional samples, resulting in a new PPA of 68% [CI 56-78]. CONCLUSIONS: During times of supply allocation and shortage of the Xpert® Xpress SARS-CoV-2 assay, the BD SARS-CoV-2 assay is well suited for test substitutions due to its high positive percent agreement. Manuscripts submitted to The Journal of Applied Laboratory Medicine 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60 21 SARS-CoV-2 Reagents for BD Max™ assays. Positive percent agreement was calculated using 22 the Xpert® Xpress SARS-CoV-2 assay as the reference method. 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60 3 34 Impact Statement 110 In summary, we found that the BD SARS-CoV-2 assay produced a higher PPA than the 111 GenMark ePlex® SARS-CoV-2 assay when using the GeneXpert® Xpress SARS-CoV-2 assay 112 as the reference method, and thus may be a better assay to use in combination or interchangeably 113 with the GeneXpert® assay to distribute test loads when supplies are limited. Analysis of the Ct 114 values for which the BD assay did not agree with the GeneXpert® assay suggest that these 115 samples may have contained quantities of viral RNA beneath the BD assay's limit of detection, 116 which is stated to be 640 genetic copies/mL by the manufacturer. In comparison, studies have 117 shown that the limit of detection for the GeneXpert® Xpress SARS-CoV-2 assay to be 100 118 copies/mL (2). This raises the concern that the BD assay will result in more false negatives than 119 the GeneXpert® assay. However, as we found in our study, specimens that were not detected by 120 the BD Max were from patients who either were determined to be recovered from infection 121 (suggesting a very low viral load in the nasopharynx or anterior nares) or were asymptomatic and 122 never developed signs and symptoms of SARS-CoV-2 infection. In this regard, the PPA between 123 the BD and GeneXpert® assays is likely higher, resulting in good interchangeability between 124 assays. To allow for more precise assay comparison, the FDA developed and shared a reference 125 panel of heat inactivated SARS-CoV-2 virus with test developers (9). Interestingly, as published 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60 7 126 in Table 2A of this study, both the BD and GeneXpert® assays were found to have a limit of 127 detection of 5,400 NAAT Detectable Units/mL, further suggesting good interchangeability 128 between the BD and GeneXpert® assays. 130 In contrast to the BD SARS-CoV-2 assay, our study demonstrated that the GenMark ePlex® 131 SARS-CoV-2 assay did not strongly agree with the GeneXpert® Xpress SARS-CoV-2 assay, 132 suggesting that the ePlex® assay may not be a good substitution should there be supply chain 133 concerns for either the BD or GeneXpert® assays. However, the lack of agreement by the 134 ePlex® assay likely is due to the lower analytical sensitivity of the assay in comparison to the 135 GeneXpert® assay. Further, we found that the direct workflow developed by GenMark did 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60 Evaluation of the Cepheid Xpert Xpress SARS-CoV-2 Test. J Clin Microbiol 58. 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60 195 Comparative Data. FDA. 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60 Xpert® Xpress SARS-CoV-2 assay as the reference method due to it being standard of care in 58 our hospital during the study period Tests were performed each instrument were collected, when available. Specifically, the Ct values for the E 65 gene target and N2 gene target were collected from the Xpert® Xpress SARS-CoV-2 assay and 66 the N1 and N2 gene targets collected from the BD SARS-CoV-2 assay. Ct values could not be 67 collected from the ePlex® SARS-CoV-2 assay as the assay detects a N gene target through DNA 68 hybridization which does not generate Ct values. Similar to the study performed by Rhoads et al Following testing, we found that the BD SARS-CoV-2 assay detected viral RNA in 72 of the 78 76 swabs (PPA 92% requirements: (a) significant contributions to the conception and 154 design, acquisition of data, or analysis and interpretation of data; (b) drafting or revising the article for 155 intellectual content Authors' Disclosures or Potential Conflicts of Interest: No authors declared any potential conflicts of Ren 165 Y, Sun Z. 2020. Multi-Center Evaluation of the Cepheid Xpert Xpress SARS-CoV-2 Assay 166 for the Detection of SARS-CoV-2 in Oropharyngeal Swab Specimens Sample-To-Answer Platforms for the Detection of SARS-CoV-2 Multicenter 9 Direct Comparison of SARS-CoV-2 Analytical Limits of Detection across 178 Seven Molecular Assays Comparing the analytical 181 performance of three SARS-CoV-2 molecular diagnostic assays Comparison of Four Molecular In Vitro 183 Diagnostic Assays for the Detection of SARS-CoV-2 in Nasopharyngeal Specimens 186 Comparison of Abbott ID Now, Diasorin Simplexa, and CDC FDA EUA methods for the 187 detection of SARS-CoV-2 from nasopharyngeal and nasal swabs from individuals 188 diagnosed with COVID-19 2020. 191 College of American Pathologists (CAP) Microbiology Committee Perspective: Caution 192 Must Be Used in Interpreting the Cycle Threshold (Ct) Value Center for Devices and Radiological Health. 2020. SARS-CoV-2 Reference Panel